Compound ID | 1228
Synonym(s): NAB741 | NAB 741 | NAB-741 | SPR-741 | SPR 741
Class: Polymyxin
| Agent Type: | Semisynthetic; Small molecule; Direct acting; Antibiotic adjuvant; |
| Spectrum of activity: | Gram-negative |
| Mechanism of action: | Membrane-active agent. Disrupts the outer membrane by direct interaction with the lipid A component of the LPS and disrupts the physical integrity of the phospholipid bilayer of the inner membrane |
| Combined with other compounds: | Yes |
| Description: | Potentiates the activity of rifampin, clarithromycin, azithromycin, mupirocin, fusidic acid and vancomycin against Escherichia coli, Klebsiella pneumoniae and Acinetobacter baumannii but not Pseudomonas aeruginosa |
| Institute where first reported: | Northern Antibiotics, Spero Therapeutics |
| Highest development stage: | Phase 1 |
| Development status: | Active |
| Reason dropped: | Replaced by SPR206; developed instead as an antibiotic adjuvant |
| External links: | |
| PubChem link: | https://pubchem.ncbi.nlm.nih.gov/compound/53323381 |
| Guide to Pharmacology: | SPR741 |
| Citations: |
|